Epicardial adipose tissue in obesity-related heart failure with preserved ejection fraction and atrial fibrillation: mechanisms, imaging, and therapeutic modulation
4 affiliations
- 1Department of Emergency, Central Hospital Affiliated to Shenyang Medical College , ,
- 2Department of Neurology, Central Hospital Affiliated to Shenyang Medical College , ,
- 3Department of Endocrinology, Central Hospital Affiliated to Shenyang Medical College , ,
- 4Department of Cardiology, Central Hospital Affiliated to Shenyang Medical College , ,
Abstract
Obesity-related heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) often coexist, but the contribution of epicardial adipose tissue (EAT) to their overlap remains uncertain. EAT is anatomically contiguous with the myocardium and can undergo inflammatory, profibrotic and metabolic remodeling in obesity. In HFpEF, greater EAT burden is associated with higher filling pressures and findings compatible with external cardiac restraint; in AF, regional peri-atrial fat is associated with abnormal conduction, fibrosis and ablation outcomes. Human EAT experiments demonstrate local profibrotic signaling, while autonomic interventions involving epicardial fat pads provide procedural evidence that does not isolate adipocyte effects. Recent invasive observations in patients with AF also link CT-defined EAT to atrial pressures and obesity-related HFpEF. Exercise, weight loss and metabolic therapies can change measured cardiac fat, although the relevant compartments and responses vary. CT attenuation is not a direct or uniformly directional measure of EAT inflammation. EAT is therefore a measurable phenotype at the HFpEF–AF interface, with stronger local experimental evidence in AF than in HFpEF. Whether changing EAT itself contributes to clinical benefit beyond systemic weight loss or other treatment effects requires longitudinal studies in patients with both conditions.
Related
- Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation
- Right Ventricular Dysfunction and Ventriculo‐Arterial Uncoupling in Heart Failure With Preserved Ejection Fraction: A Phenotype‐Specific Review of Mechanisms, Diagnosis, and Therapeutic Strategies
- Mechanisms and therapeutic prospects of short-chain fatty acids in neonatal hypoxic–ischemic encephalopathy via modulation of mitochondrial dysfunction and endoplasmic reticulum stress
- Substrate Comprising Fibrosis and Epicardial Adipose Tissue-Associated Electrophysiological Remodeling Can Sustain Atrial Fibrillation Drivers: Insights from Image-Personalized Computational Simulations
- Epicardial Adipose Tissue as a Dynamic Modulator of Coronary Artery Disease Phenotypes: Pathophysiology and Therapeutic Implications
BibTeX
@article{zhu2026epicardial,
title = {{Epicardial adipose tissue in obesity-related heart failure with preserved ejection fraction and atrial fibrillation: mechanisms, imaging, and therapeutic modulation}},
author = {Qi Zhu and Tiance Xu and Chen Yang and Lili Tan},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1976969},
url = {https://europepmc.org/article/PMC/PMC13691726},
note = {CC BY},
}
RIS
TY - JOUR
TI - Epicardial adipose tissue in obesity-related heart failure with preserved ejection fraction and atrial fibrillation: mechanisms, imaging, and therapeutic modulation
AU - Qi Zhu
AU - Tiance Xu
AU - Chen Yang
AU - Lili Tan
PY - 2026
DA - 2026/10/09
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1976969
UR - https://europepmc.org/article/PMC/PMC13691726
AB - Obesity-related heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) often coexist, but the contribution of epicardial adipose tissue (EAT) to their overlap remains uncertain. EAT is anatomically contiguous with the myocardium and can undergo inflammatory, profibrotic and metabolic remodeling in obesity. In HFpEF, greater EAT burden is associated with higher filling pressures and findings compatible with external cardiac restraint; in AF, regional peri-atrial fat is associated with abnormal conduction, fibrosis and ablation outcomes. Human EAT experiments demonstrate local profibrotic signaling, while autonomic interventions involving epicardial fat pads provide procedural evidence that does not isolate adipocyte effects. Recent invasive observations in patients with AF also link CT-defined EAT to atrial pressures and obesity-related HFpEF. Exercise, weight loss and metabolic therapies can change measured cardiac fat, although the relevant compartments and responses vary. CT attenuation is not a direct or uniformly directional measure of EAT inflammation. EAT is therefore a measurable phenotype at the HFpEF–AF interface, with stronger local experimental evidence in AF than in HFpEF. Whether changing EAT itself contributes to clinical benefit beyond systemic weight loss or other treatment effects requires longitudinal studies in patients with both conditions.
SN - 1664-2392
ER -